News
1 October 2026
Fonko Strengthens Indonesia’s Oncology Industry Capacity
JAKARTA — PT Fonko International Pharmaceuticals has recorded several key milestones in the development of oncology drug manufacturing in Indonesia. These achievements include securing European Union Good Manufacturing Practice (EU GMP) certification in 2025, developing a range of "first copy" products for cancer therapy, and obtaining halal certification for its…
25 September 2026
Consistently Maintaining Halal Standards, Dexa Group Wins IHYA 2026
TANGERANG — PT Ferron Par Pharmaceuticals, a member of Dexa Group, has won the 2026 Indonesia Halal Industry Award (IHYA) from the Ministry of Industry of the Republic of Indonesia in the Large Industrial Enterprise Category, Subcategory of Best Pharmaceuticals and Traditional Medicines. This award recognizes Dexa Group’s consistency in…
24 September 2026
From Medications to Facilities, Ferron Strengthens Support for Cancer Patients
JAKARTA — Indonesia recorded 474,083 new cases and 283,299 deaths due to cancer, according to 2024 Global Cancer Observatory (GLOBOCAN) data. This situation underscores the critical role of Ferron Par Pharmaceuticals in expanding its support for cancer patients—from delivering access to medications to strengthening chemotherapy support facilities through the provision…
15 December 2021
Dexa Group Donates Medicines through BNPB for Semeru Eruption Victims
The national pharmaceutical company Dexa Group participated in donating a number of medicines through the National Disaster Management Agency (BNPB) to treat the health of residents affected by the eruption of Mount Semeru in Lumajang, East Java. According to BPNP data on December 6, 2021, residents affected by the eruption…
8 December 2021
Dexa Group Appreciated by Government for Contribution to Improving National Industry Competitiveness through OMAI Research and Innovation
Taking an active role in increasing the competitiveness of the national industry through research and sustainable technological innovation in the pharmaceutical sector, Dexa Laboratories of Biomolecular Sciences (DLBS) received the Rintisan Teknologi Industri 2021 award from the Ministry of Industry of the Republic of Indonesia. The award was handed over…
22 October 2021
Dexa Medica Wins Primaniyarta Award 2021 for OMAI Stimuno’s Marketing Achievements Abroad
PT Dexa Medica won the Primaniyarta 2021 award for the New Market Pioneer category. The Primaniyarta 2021 winners' awards were announced at the opening ceremony of the Trade Expo Indonesia Digital Edition (TEI DE), on Thursday, October 21, 2021. The President of the Republic of Indonesia, Mr. Joko Widodo (Jokowi)…
13 October 2021
HerbaASIMOR Wins Indonesia Digital Marketing Champion 2021 Award
Dexa Medica through HerbaASIMOR won the Indonesia Digital Marketing Champion 2021 award as the 1st Digital Marketing Champion 2021 in the Healthcare Products category with the title Very Good. This award was achieved for Dexa Medica's achievements in improving business performance through digital platforms. The award was given by SWA's…
1 September 2021
Dexa Group Ramps Up Business in SE Asia by Launching Glorious Dexa Singapore Pte. Ltd.
Dexa Group, the leading pharmaceutical company from Indonesia, is ramping up its business in Southeast Asia with the launch of Glorious Dexa Singapore, Pte. Ltd. (GDS) based in Singapore. Dexa Group has exported medicines to various countries starting with Myanmar since 1993 and began exporting international standard medicines to Singapore…
23 August 2021
Government Appreciates Industry 4.0 Implementation by Dexa Group
The Ministry of Industry continues to improve the competitiveness of the national industry through the transformation towards industry 4.0. In this regard, as a leading international pharmaceutical company in Indonesia, Dexa Group has implemented Industry 4.0 in the production process to distribution. President Director of PT Ferron Par Pharmaceuticals, Mr.…
2 August 2021
Regdanvimab Reduced The Risk of COVID-19-related Hospitalization or Death for Patients with Comorbidities
Regdanvimab (RegkironaTM) is recommended to treat confirmed COVID-19 in adult patients who do not require supplemental oxygen therapy and are at high risk of progressing to severe COVID-19. The recommended dosage of Regdanvimab is a single intravenous infusion of 40 mg/kg. Treatment should be initiated as soon as possible after…